Protagonist Therapeutics (PTGX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.29
- Estimate
- $1.94
- Surprise
- +18.3%
- Revenue (period 2026-06-30)
- $213.5M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Protagonist Therapeutics (PTGX) beat the $1.94 estimate with diluted EPS of $2.29 — a large 18.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PTGX Buy (Wait) at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +18.3% surprise compares with a +25.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Pipeline: Icotyde and rusfertide
- Concentration risk — Counterparty: JNJ
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $148.18
- Entry target
- $142.36
- Price target
- $151.98
- Stop
- $130.65
- Upside to target
- +2.6%
- Reward-to-risk
- 0.3:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
PTGX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.59B
- P/E (fwd)
- -744.1
- P/E (ttm)
- 142.5
- 52-week range
- $57.90–$160.81
- Off 52-week high
- 7.9%
- RSI (14)
- 39
- Volume vs avg
- 0.94×
- Score today
- 5.5/10